Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
Risk of reinfection is a concern after successful hepatitis C treatment

People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) – achieving cure rates similar to those of the population as a whole –

Published
9 hours ago
By
Liz Highleyman
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV

The e-poster presented at EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure reports that 100 percent of patients receiving treatment for as short as six weeks with a triple combination of once-daily (QD) AL-335 800mg and simeprevir (SMV) 75mg with 50mg every other day (QOD) of ODV achieved a sustained viral response 12 weeks after the completion of treatment (SVR12).

Published
26 September 2016
From
Achillion press release
EASL issues new hepatitis C treatment recommendations for all genotypes

The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris.

Published
26 September 2016
By
Liz Highleyman
NICE says yes to another hepatitis C drug

NICE has published new draft guidance which recommends sofosbuvir-velpatasvir (Epclusa) – an anti-viral drug that offers patients with chronic hepatitis C a potential cure.

Published
26 September 2016
From
NICE
Exviera, Viekirax regimen shows high SVR in HCV genotype 1b after 8 weeks

New data from the GARNET study — presented today in Paris at the 2016 EASL Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure — showed 98% of patients with hepatitis C virus genotype 1b infection without cirrhosis achieved sustained virologic response 12 weeks after treatment with Exviera plus Viekirax without ribavirin, with some showing high rates after 8 weeks.

Published
26 September 2016
From
Healio
New Study: Negotiated Hepatitis C Prescription Drug Costs in United States Often Lower than in Price-Controlled European Countries and Japan

A new report, "Comparison of Hepatitis C Treatment Costs," shows Hepatitis C drug prices, specifically negotiated by pharmacy benefit managers (PBMs) in Medicare Part D in 2015, were typically lower than prices in Europe and Japan.

Published
20 September 2016
From
Yahoo News
HCV treatment is effective and may work as prevention for people who inject drugs

Hepatitis C treatment for people who inject drugs is as safe and effective as it is for non-drug-users – with cure rates exceeding 90% – and treating

Published
20 September 2016
By
Liz Highleyman
Behind Battle Over Drug Prices, Quiet Money From Big Pharma

Is there a conflict of interest for hepatitis C advocates in accepting funds from pharmaceutical companies and representing the interests of patients when questions of drug pricing and access to treatment are being debated?

Published
19 September 2016
From
Bloomberg
NHS funding cuts ‘forcing people to buy medicine through Facebook’

Patients and researchers say the medicine is safe, however pharmacists have warned that medicine bought online could be placebo pills or contain dangerous ingredients.

Published
16 September 2016
From
The Independent
Hepatitis C vaccine development shows progress but scientific barriers remain

An effective vaccine may be necessary to eliminate hepatitis C virus (HCV) but development has been hampered by several challenges including the variability of the virus and

Published
14 September 2016
By
Liz Highleyman
← First12345...161Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close